Voyager Therapeutics (VYGR) Misses Q4 EPS by 11c

Voyager Therapeutics (NASDAQ: VYGR) reported Q4 EPS of ($0.57), $0.11 worse than the analyst estimate of ($0.46). Revenue for the quarter came in at $2.36 million versus the consensus estimate of $4.01 million.

For earnings history and earnings-related data on Voyager Therapeutics (VYGR) click here.

You May Also Be Interested In

• North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
• CAE, Inc. (CAE) Tops Q1 EPS by 2c, Beats on Revenue; Offers FY27 EPS Guidance
• Acrivon Therapeutics, Inc. (ACRV) Tops Q2 EPS by 21c